Deletion of Rapgef6, a candidate schizophrenia susceptibility gene, disrupts amygdala function in mice

DSpace/Manakin Repository

Deletion of Rapgef6, a candidate schizophrenia susceptibility gene, disrupts amygdala function in mice

Citable link to this page

 

 
Title: Deletion of Rapgef6, a candidate schizophrenia susceptibility gene, disrupts amygdala function in mice
Author: Levy, R J; Kvajo, M; Li, Y; Tsvetkov, E; Dong, W; Yoshikawa, Y; Kataoka, T; Bolshakov, V Y; Karayiorgou, M; Gogos, J A

Note: Order does not necessarily reflect citation order of authors.

Citation: Levy, R J, M Kvajo, Y Li, E Tsvetkov, W Dong, Y Yoshikawa, T Kataoka, V Y Bolshakov, M Karayiorgou, and J A Gogos. 2015. “Deletion of Rapgef6, a candidate schizophrenia susceptibility gene, disrupts amygdala function in mice.” Translational Psychiatry 5 (6): e577. doi:10.1038/tp.2015.75. http://dx.doi.org/10.1038/tp.2015.75.
Full Text & Related Files:
Abstract: In human genetic studies of schizophrenia, we uncovered copy-number variants in RAPGEF6 and RAPGEF2 genes. To discern the effects of RAPGEF6 deletion in humans, we investigated the behavior and neural functions of a mouse lacking Rapgef6. Rapgef6 deletion resulted in impaired amygdala function measured as reduced fear conditioning and anxiolysis. Hippocampal-dependent spatial memory and prefrontal cortex-dependent working memory tasks were intact. Neural activation measured by cFOS phosphorylation demonstrated a reduction in hippocampal and amygdala activation after fear conditioning, while neural morphology assessment uncovered reduced spine density and primary dendrite number in pyramidal neurons of the CA3 hippocampal region of knockout mice. Electrophysiological analysis showed enhanced long-term potentiation at cortico–amygdala synapses. Rapgef6 deletion mice were most impaired in hippocampal and amygdalar function, brain regions implicated in schizophrenia pathophysiology. The results provide a deeper understanding of the role of the amygdala in schizophrenia and suggest that RAPGEF6 may be a novel therapeutic target in schizophrenia.
Published Version: doi:10.1038/tp.2015.75
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490285/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:17820828
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters